Spark Biomedical unveils the Sparrow® Link Research Platform designed to enable research teams to customize the transcutaneous auricular neurostimulation tAN power of the FDA-cleared Sparrow Ascent.

The Centers for Medicare and Medicaid Services codes will help increase accessibility to wearable bioelectric medicine for opioid withdrawal.

Entrepreneur of the Year celebrates ambitious entrepreneurs who are shaping the future.

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

The partnership focuses on testing wearable neurostimulation to prevent and treat acute stress reaction in the military. 

Spark Biomedical Inc., a U.S. leader in wearable neurostimulation solutions, is proud to announce the launch of telehealth services for their recently FDA-cleared product, Sparrow Ascent.

This FDA-cleared wearable neuromodulation system offers game-changing access for patients to start the road to recovery without interruptions to daily living

The Hartford County Maryland Health Department is making the path to Opioid Use Disorder (OUD) recovery more attainable for local patients. The first step, providing patients access to the Sparrow Therapy System to overcome withdrawal symptoms. 

Ending opioid addiction in the Lowcountry is the goal of the Medical University of South Carolina staff as they get ready to launch a multi-year clinical trial to test a new device aimed at helping patients with opioid withdrawals.

Collaborative study awarded to the University of Texas Medical Branch, Medical University of South Carolina, and Spark Biomedical